Tag: cannabis pharmaceuticals market trends

Uncover key drivers, emerging technologies, and competitive movements shaping the cannabis pharmaceuticals market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Cannabis Pharmaceuticals Market between 2026 and 2030?

The cannabis pharmaceuticals market has witnessed rapid expansion in recent years. It is forecast to rise from $9.43 billion in 2025 to $14.74 billion in 2026, registering a compound annual growth rate (CAGR) of 56.3%. The market’s historical development can be ascribed to several factors, including the growing acceptance of cannabinoids’ therapeutic benefits, the increase in medical cannabis prescriptions, the availability of early cannabis-based drugs, the expansion of hospital-based pain management initiatives, and regulatory approvals for certain cannabis pharmaceuticals.

The cannabis pharmaceuticals market is projected for remarkable expansion over the coming years, with its valuation set to reach $85.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 55.3%. This anticipated growth stems from several factors, including escalating investments in clinical trials for cannabis-derived drugs, a surging need for consistent cannabinoid formulations, broader applications in neurology and oncology, increased integration of cannabis pharmaceuticals within hospital settings, and greater alignment of regulations across various markets. Key trends anticipated during this period encompass the accelerated creation of prescription-strength cannabis medicines, a heightened focus on clinical validation and extensive trials, expanded therapeutic use in neurological conditions and pain management, the enlargement of regulated pharmaceutical development pipelines, and a stronger emphasis on precise dosing.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

Which Drivers Are Expected To Impact The Cannabis Pharmaceuticals Market During The Forecast Period?

An anticipated increase in epilepsy cases is projected to fuel the expansion of the cannabis pharmaceuticals market moving ahead. Epilepsy is defined as a neurological condition marked by repeated, spontaneous seizures resulting from atypical electrical activity within the brain. This increase in epilepsy occurrences can be linked to improved diagnostic methods, greater public awareness, and more comprehensive reporting, in addition to potential environmental, genetic, and lifestyle factors. Cannabis-based medications have demonstrated promise in managing epilepsy by employing cannabinoids such as CBD to lessen the occurrence and intensity of seizures for individuals unresponsive to conventional anti-epileptic treatments. As an illustration, the World Health Organization, a Switzerland-based global health agency, reported in February 2024 that the global population affected by epilepsy had climbed to approximately 50 million in 2024. Consequently, the growing prevalence of epilepsy is propelling the development of the cannabis pharmaceuticals market.

How Is The Cannabis Pharmaceuticals Market Divided Into Segments?

The cannabis pharmaceuticals market covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals, Synthetic Cannabinoids

2) By Therapeutic Application: Cancer, Neurological Disorders, Pain Management

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Government-Authorized Medical Cannabis Dispensaries

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals, CBD-Based Pharmaceuticals, Combination of THC and CBD Pharmaceuticals, Other Cannabinoid-Based Formulations

2) By Synthetic Cannabinoids: Synthetic THC Analogues, Synthetic CBD Analogues, Synthetic Cannabinoid Receptor Agonists

What Upcoming Trends Are Likely To Define The Future Path Of The Cannabis Pharmaceuticals Market?

Major enterprises in the cannabis pharmaceuticals sector are concentrating on creating novel products, such as sophisticated medical cannabis formulations, to tackle various medical ailments and enhance patient results. These advanced medical cannabis formulations are specifically engineered cannabis-based offerings, refined for therapeutic application, incorporating exact quantities of cannabinoids such as THC and CBD. For instance, in April 2024, Canexis Pharma AG, a pharmaceutical firm based in Switzerland, secured manufacturing and narcotics licenses for cannabis pharmaceuticals from Swissmedic. These authorizations enable the company to produce high-quality medicinal active ingredients derived from CBD and THC. This development positions Canexis to cater to the increasing demand for medical cannabis both within Switzerland and internationally. By acquiring these licenses, the company showcases its adherence to rigorous regulatory benchmarks, thereby bolstering its trustworthiness and capacity to contribute to the rapidly expanding medical cannabis market.

Which Key Players Are Driving Competition In The Cannabis Pharmaceuticals Market?

Major companies operating in the cannabis pharmaceuticals market are Tilray Inc., Canopy Growth Corporation, Aurora Cannabis Inc., Aphria Inc., Cronos Group, GW Pharmaceuticals plc, Jazz Pharmaceuticals plc, Organigram Holdings Inc., Aleafia Health Inc., Avicanna Inc., Enveric Biosciences Inc., Auxly Cannabis Group Inc., Emerald Health Therapeutics Inc., Medical Marijuana Inc., Valens Company Inc., Curaleaf Holdings Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

Which Region Is Projected To Lead The Cannabis Pharmaceuticals Market During The Forecast Period?

North America was the largest region in the cannabis pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cannabis Pharmaceuticals Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Browse Through More Reports Similar to the Global Cannabis Pharmaceuticals Market 2026, By The Business Research Company

Cannabis Cultivation Market Report 2026

https://www.thebusinessresearchcompany.com/report/cannabis-cultivation-global-market-report

Cannabis Capsule Market Report 2026

https://www.thebusinessresearchcompany.com/report/cannabis-capsule-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Cannabis Pharmaceuticals Market?

The market size for cannabis pharmaceuticals has seen significant expansions in the past few years. From a worth of $6.03 billion in 2024, it is expected to blossom to $9.43 billion in 2025, with a projected compound annual growth rate (CAGR) of 56.4%. Factors contributing to the growth in the historic period include increased legalization of medicinal cannabis, heightened awareness of the therapeutic benefits of cannabinoids, a rise in chronic and neurological conditions, positive changes in regulatory frameworks, amplified investments by pharmaceutical companies, and shifting attitudes toward the use of cannabis in medical treatments.

In the coming years, the cannabis pharmaceuticals market size is predicted to experience significant expansion, reaching $55.53 billion in 2029, and exhibiting a compound annual growth rate (CAGR) of 55.8%. This substantial growth during the anticipated period is due to several factors such as the increasing approval of regulations, enhanced understanding of the advantages of medical cannabis, its increasing use in managing pain and neurological issues, the growth in chronic disease prevalence, the innovation of drug delivery systems, and the implantation of favorable reimbursement policies. The estimated period will also see major trends like advancements in the extraction technology for cannabinoids, the development of targeted drug delivery systems, the utilization of synthetic cannabinoid formulations, better methodologies for clinical trials, and the use of artificial intelligence in drug discovery.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What Are The Primary Factors Supporting The Cannabis Pharmaceuticals Market Expansion?

The increase in epilepsy cases is projected to spur the growth of the cannabis pharmaceuticals industry. Epilepsy, a neurological condition marked by repeated, unprovoked seizures due to irregular brain electrical activity is on the rise. The increased number of epilepsy cases can be owed to better diagnosis, increased consciousness, improved reporting, and potential environmental, genetic, and lifestyle factors. Cannabis pharmaceuticals, utilizing cannabinoids like CBD, have demonstrated potential in managing epilepsy by reducing the scale and intensity of seizures in patients unresponsive to standard anti-epileptic medicines. For example, in April 2022, the Belgium-based non-profit European Brain Council revealed that over 600 neurological diseases and nearly 300 psychiatric conditions plague millions worldwide, including 65 million epileptics. Additionally, in July 2024, according to Canada’s Alzheimer Society, on January 1, 2025, an estimated 771,939 Canadians will suffer from dementia, a number projected to approach one million by 2030. As a result, the escalating epilepsy cases are propelling the expansion of the cannabis pharmaceuticals industry.

Which Segments Define The Structure Of The Cannabis Pharmaceuticals Market?

The cannabis pharmaceuticalsmarket covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions

3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management

4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids

What Strategic Shifts And Innovations Are Influencing The Cannabis Pharmaceuticals Market?

Key corporations in the cannabis pharmaceutical sector are prioritizing the creation of ground-breaking products such as advanced medical cannabis formulations. These are aimed at catering to a variety of health issues and enhancing patient results. Advanced medical cannabis formulas are custom-made cannabis-centric products, meticulously designed for therapeutic use, encompassing accurate doses of cannabinoids like THC and CBD. For example, in April 2024, Switzerland’s pharmaceutical firm, Canexis Pharma AG, was awarded manufacturing and narcotics certifications by Swissmedic, pertaining to cannabis pharmaceuticals. Such endorsements allow the firm to manufacture top-quality medicinal ingredients originating from CBD and THC. This progress situates Canexis in a position to satisfy the burgeoning requirement for medical cannabis, both domestically and internationally. By earning these accreditations, the firm showcases its adherence to rigorous regulatory norms, boosting its trustworthiness and potential to make significant contributions to the swiftly expanding medical cannabis sector.

Who Are The Primary Market Leaders In The Cannabis Pharmaceuticals Market?

Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte’s Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

What Regional Factors Are Accelerating Growth In The Cannabis Pharmaceuticals Market?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Browse Through More Reports Similar to the Global Cannabis Pharmaceuticals Market 2025, By The Business Research Company

Cannabis Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-products-global-market-report

Cannabis Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

Cannabis Cultivation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cannabis-cultivation-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Cannabis Pharmaceuticals Market Through 2034?

The size of the cannabis pharmaceuticals market has expanded significantly in the past few years. The market is estimated to increase from a value of $6.03 billion in 2024 to $9.43 billion in 2025, growing at a compounded annual growth rate (CAGR) of 56.4%. The growth experienced in the historical period can be credited to factors such as the growing legalization of medical cannabis, heightened awareness about the therapeutic benefits of cannabinoids, increased occurrence of chronic and neurological disorders, favorable regulatory structures, increased investments in pharmaceuticals, and a change in the public attitudes towards the use of cannabis in healthcare.

The expected expansion of the cannabis pharmaceuticals market in the coming years is significant, with predictions showing growth to $55.53 billion in 2029, increasing at a compound annual growth rate (CAGR) of 55.8%. This anticipated surge during the forecast period is largely due to factors such as rising regulatory approvals, broader understanding of the medicinal benefits of cannabis, its growing usage in managing pain and neurological disorders, increasing occurrence of chronic diseases, advancements in drug delivery systems, and the establishment of supportive reimbursement policies. Future trends include improvements in cannabinoid extraction processes, the development of specific drug delivery systems, the use of synthetic cannabinoid formulations, enhanced clinical trial methods, and the incorporation of artificial intelligence in drug research.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Cannabis Pharmaceuticals Market?

An increase in epilepsy instances is anticipated to fuel the expansion of the cannabis pharmaceuticals market. Epilepsy, a neurological disorder distinguished by recurrent, unwarranted seizures caused by irregular electrical activities in the brain, has seen a rise due to improved diagnosis, heightened awareness, as well as superior reporting. Additionally, factors like environmental, genetic, and lifestyle influences could be contributors. Cannabis pharmaceuticals, utilizing cannabinoids like CBD, have demonstrated potential in managing epilepsy. They can minimize the frequency and severity of seizures in patients who otherwise show minimal response to conventional anti-epileptic drugs. For Example, as reported by the European Brain Council, a non-profit organization based in Belgium, over 600 neurological disorders and nearly 300 psychiatric conditions plague millions worldwide, including 65 million epilepsy patients, as of April 2022. Additionally, according to the Alzheimer Society of Canada, a health charity situated in Canada, the estimates suggest that 771,939 Canadians will be suffering from dementia on January 1, 2025. This number is projected to reach nearly one million by 2030. Thus, the escalating epilepsy cases are boosting the cannabis pharmaceuticals market’s growth.

Which Key Market Segments Comprise the Cannabis Pharmaceuticals Market and Drive Its Revenue Growth?

The cannabis pharmaceuticalsmarket covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions

3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management

4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Which Areas Are Leading Regions in the Cannabis Pharmaceuticals Market Expansion Across the Globe?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theCannabis Pharmaceuticals Market Direction?

The primary players in the cannabis pharmaceuticals marketplace are honing in on crafting pioneering products such as sophisticated medical cannabis compounds. These are intended to address various medical scenarios and enhance patient recovery rates. Sophisticated medical cannabis compounds denote uniquely formulated cannabis-rooted products, tailored for a therapeutic application that incorporate accurate dosages of cannabinoids including THC and CBD. Take for instance, Canexis Pharma AG, a biomedical firm based in Switzerland, who in April 2024, obtained manufacturing and narcotics licenses from Swissmedic, specific for cannabis pharmaceuticals. These permissions facilitate the firm to manufacture top-quality medicinal active ingredients originating from CBD and THC, thus enhancing Canexis’s ability to cater to the surging requirement for medicinal cannabis in Switzerland and internationally. By securing these licenses, the firm illustrates its adherence to rigorous regulatory standards, escalating its dependability and capacity to contribute to the fast-paced evolution of the medical cannabis market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

How Is the Cannabis Pharmaceuticals Market Conceptually Defined?

Cannabis pharmaceuticals are prescription-grade medications made from cannabis-derived compounds, designed to address particular health conditions and produced under strict clinical and regulatory standards. These pharmaceuticals utilize the therapeutic benefits of cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), to treat conditions including chronic pain, epilepsy, and multiple sclerosis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Cannabis Pharmaceuticals Market Through 2034?

The size of the cannabis pharmaceuticals market has expanded significantly in the past few years. The market is estimated to increase from a value of $6.03 billion in 2024 to $9.43 billion in 2025, growing at a compounded annual growth rate (CAGR) of 56.4%. The growth experienced in the historical period can be credited to factors such as the growing legalization of medical cannabis, heightened awareness about the therapeutic benefits of cannabinoids, increased occurrence of chronic and neurological disorders, favorable regulatory structures, increased investments in pharmaceuticals, and a change in the public attitudes towards the use of cannabis in healthcare.

The expected expansion of the cannabis pharmaceuticals market in the coming years is significant, with predictions showing growth to $55.53 billion in 2029, increasing at a compound annual growth rate (CAGR) of 55.8%. This anticipated surge during the forecast period is largely due to factors such as rising regulatory approvals, broader understanding of the medicinal benefits of cannabis, its growing usage in managing pain and neurological disorders, increasing occurrence of chronic diseases, advancements in drug delivery systems, and the establishment of supportive reimbursement policies. Future trends include improvements in cannabinoid extraction processes, the development of specific drug delivery systems, the use of synthetic cannabinoid formulations, enhanced clinical trial methods, and the incorporation of artificial intelligence in drug research.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Cannabis Pharmaceuticals Market?

An increase in epilepsy instances is anticipated to fuel the expansion of the cannabis pharmaceuticals market. Epilepsy, a neurological disorder distinguished by recurrent, unwarranted seizures caused by irregular electrical activities in the brain, has seen a rise due to improved diagnosis, heightened awareness, as well as superior reporting. Additionally, factors like environmental, genetic, and lifestyle influences could be contributors. Cannabis pharmaceuticals, utilizing cannabinoids like CBD, have demonstrated potential in managing epilepsy. They can minimize the frequency and severity of seizures in patients who otherwise show minimal response to conventional anti-epileptic drugs. For Example, as reported by the European Brain Council, a non-profit organization based in Belgium, over 600 neurological disorders and nearly 300 psychiatric conditions plague millions worldwide, including 65 million epilepsy patients, as of April 2022. Additionally, according to the Alzheimer Society of Canada, a health charity situated in Canada, the estimates suggest that 771,939 Canadians will be suffering from dementia on January 1, 2025. This number is projected to reach nearly one million by 2030. Thus, the escalating epilepsy cases are boosting the cannabis pharmaceuticals market’s growth.

Which Key Market Segments Comprise the Cannabis Pharmaceuticals Market and Drive Its Revenue Growth?

The cannabis pharmaceuticalsmarket covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions

3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management

4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Which Areas Are Leading Regions in the Cannabis Pharmaceuticals Market Expansion Across the Globe?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theCannabis Pharmaceuticals Market Direction?

The primary players in the cannabis pharmaceuticals marketplace are honing in on crafting pioneering products such as sophisticated medical cannabis compounds. These are intended to address various medical scenarios and enhance patient recovery rates. Sophisticated medical cannabis compounds denote uniquely formulated cannabis-rooted products, tailored for a therapeutic application that incorporate accurate dosages of cannabinoids including THC and CBD. Take for instance, Canexis Pharma AG, a biomedical firm based in Switzerland, who in April 2024, obtained manufacturing and narcotics licenses from Swissmedic, specific for cannabis pharmaceuticals. These permissions facilitate the firm to manufacture top-quality medicinal active ingredients originating from CBD and THC, thus enhancing Canexis’s ability to cater to the surging requirement for medicinal cannabis in Switzerland and internationally. By securing these licenses, the firm illustrates its adherence to rigorous regulatory standards, escalating its dependability and capacity to contribute to the fast-paced evolution of the medical cannabis market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

How Is the Cannabis Pharmaceuticals Market Conceptually Defined?

Cannabis pharmaceuticals are prescription-grade medications made from cannabis-derived compounds, designed to address particular health conditions and produced under strict clinical and regulatory standards. These pharmaceuticals utilize the therapeutic benefits of cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), to treat conditions including chronic pain, epilepsy, and multiple sclerosis.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Cannabis Pharmaceuticals Market Growth in 2025?

The size of the pharmaceutical cannabis market has experienced rapid expansion in the recent past. This growth is forecasted to leap from $6.03 billion in 2024 to a whopping $9.45 billion in 2025, with a compound annual growth rate (CAGR) of 56.66%. The substantial growth witnessed in the historical period is due to several factors including heightened legalization of medicinal cannabis, increased awareness of the therapeutic benefits of cannabinoids, escalating incidences of chronic and neurological conditions, favorable regulations, significant investment by pharmaceutical companies, and a shifting public opinion regarding the use of cannabis in the healthcare sector.

What Is the Forecast for the Cannabis Pharmaceuticals Market Size Through 2029?

Over the coming years, the cannabis pharmaceuticals market is projected to undergo sizeable expansion. By 2029, it is forecasted to reach a valuation of $56.37 billion, achieving a compound annual growth rate (CAGR) of 56.29%. The projected growth throughout this period can be linked to various factors such as increased regulatory approval, heightened public awareness of the health benefits of medical cannabis, the application of cannabis in treating pain and neurological disorders, a rise in chronic illnesses, advancement in drug delivery systems, and the formulation of beneficial reimbursement policies. The period is also likely to witness trends like progress in cannabinoid extraction technologies, creation of targeted drug delivery systems, preference for synthetic cannabinoid formulations, enhancement of clinical trial methods, and the incorporation of artificial intelligence in drug discovery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What are the Key Market Players in Cannabis Pharmaceuticals Market and How They’re Evolving?

Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte’s Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

What Are the Primary Growth Drivers in the Cannabis Pharmaceuticals Market?

The growth of the cannabis pharmaceuticals market is largely due to the increasing prevalence of epilepsy. Epilepsy, a neurological condition marked by frequent, unprovoked seizures resulting from abnormal brain electrical activity, is becoming more common. This increase is due to improved detection, heightened awareness, and more thorough reporting, in addition to likely environmental, genetic, and lifestyle factors. Cannabis pharmaceuticals, particularly cannabinoids like CBD, have shown promise in controlling epilepsy, lowering the frequency and intensity of seizures in patients who do not see benefits from typical anti-epileptic medicines. For example, the Belgium-based non-profit European Brain Council reported in April 2022 that over 600 neurological diseases and about 300 psychiatric conditions affect millions worldwide, 65 million of which suffer from epilepsy. Furthermore, the Alzheimer Society of Canada, a Canadian health charity, estimated in July 2024 that by January 1, 2025, 771,939 Canadians will be diagnosed with dementia, with this number expected to approach one million by 2030. Therefore, the escalating incidence of epilepsy is propelling the expansion of the cannabis pharmaceuticals market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

What Are the Leading Segments in the Global Cannabis Pharmaceuticals Industry?

The cannabis pharmaceuticals market covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals, Cannabis Extracts, Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets, Oils And Tinctures, Topical Solutions

3) By Therapeutic Application: Cancer, Neurological Disorders, Pain Management

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End-User: Hospitals And Clinics, Rehabilitation Centers, Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals, CBD-Based Pharmaceuticals, Combination of THC and CBD Pharmaceuticals, Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts, Broad-Spectrum Cannabis Extracts, Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues, Synthetic CBD Analogues, Synthetic Cannabinoid Receptor Agonists, Designer Synthetic Cannabinoids

What Are the Key Market Trends in the Cannabis Pharmaceuticals Industry?

Significant players in the medical cannabis market, like Canexis Pharma AG, are concentrating their efforts on the creation of novel products such as advanced medical cannabis formulations. These products are specially engineered for therapeutic use and utilize precise measures of cannabinoids such as THC and CBD to address various medical conditions and boost patient outcomes. For instance, in April 2024, Canexis, a Swiss pharmaceutical firm, was granted manufacturing and narcotic licenses from Swissmedic to carry out cannabis pharmaceuticals production. The licensing enables the company to generate premium-grade medicinal components from CBD and THC. The accreditation not only strengthens Canexis’s reliability and compliance with stringent regulatory norms but also positions it to meet the increasing global demand for medical cannabis in Switzerland and around the world.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

What Is the Regional Outlook for the Cannabis Pharmaceuticals Market?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

This Report Delivers Insight On:

1. How big is the cannabis pharmaceuticals market, and how is it changing globally?

2. Who are the major companies in the cannabis pharmaceuticals market, and how are they performing?

3. What are the key opportunities and risks in the cannabis pharmaceuticals market right now?

4. Which products or customer segments are growing the most in the cannabis pharmaceuticals market?

5. What factors are helping or slowing down the growth of the cannabis pharmaceuticals market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Cannabis Pharmaceuticals Market?

An increase in epilepsy occurrences is anticipated to propel the cannabis pharmaceuticals market in the future. Epilepsy is a neurological disorder marked by frequent, unprovoked seizures caused by irregular electrical activity in the brain. This surge in epilepsy cases might be due to improved diagnostics, heightened awareness, better reporting, along with potential environmental, lifestyle and genetic factors. Cannabis pharmaceuticals have demonstrated capabilities in controlling epilepsy, with cannabinoids like CBD in reducing the intensity and number of seizures in patients who are unresponsive to conventional anti-epileptic drugs. For example, as of April 2022, the European Brain Council, a Belgian non-profit organization, reports that more than 600 neurological diseases and close to 300 psychiatric conditions afflict millions worldwide, which includes 65 million epilepsy patients. Also, in July 2024, the Alzheimer Society of Canada, a Canadian health charity, suggests that over 771,939 Canadians are likely to be diagnosed with dementia by January 1, 2025, and almost one million are expected suffer from it by 2030. As a consequence, the increase in epilepsy cases is fueling the expansion of the cannabis pharmaceuticals market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

#What is the Projected CAGR for the Cannabis Pharmaceuticals Market Size from 2025 to 2034?

The market size for cannabis pharmaceuticals has been expanding drastically over the past few years. It is predicted to increase from $6.03 billion in 2024 to $9.45 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 56.66%. Factors contributing to the growth during the historic period include the expanding legalization of medicinal marijuana, increased understanding of the therapeutic benefits of cannabinoids, growth in the occurrence of chronic and neurological health issues, accommodating regulatory environments, growing investments in the pharmaceutical sector, and changing attitudes of the public toward the use of cannabis in healthcare.

In the upcoming years, the cannabis pharmaceuticals market size is projected to experience stellar growth, anticipated to reach $56.37 billion by 2029, with a compound annual growth rate (CAGR) of 56.29%. This growth within the forecast period can be credited to several factors such as the rise in regulatory approvals, mounting recognition of the medical advantages of cannabis, wider application in pain and neurological disorder treatment, an upsurge in chronic illnesses, innovative drug delivery systems, and the establishment of supportive reimbursement policies. Influential trends during the forecast period are expected to be advancements in cannabinoid extraction technologies, the development of targeted drug delivery systems, the use of synthetic cannabinoid formulations, enhancement of clinical trial methodologies, and employment of artificial intelligence for drug discovery.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

What Are the Most Significant Market Trends Transforming theCannabis Pharmaceuticals Market?

Prominent corporations in the cannabis pharmaceuticals market are concentrating on the creation of novel, innovative products, notably advanced medical cannabis formulations. These are intended to treat a variety of health conditions and improve the overall wellbeing of patients. Advanced medical cannabis formulations are cannabis-based products that are specifically created for therapeutic purposes. They contain accurate doses of cannabinoids such as THC and CBD. For example, in April 2024, Switzerland’s pharmaceutical firm, Canexis Pharma AG, was granted manufacturing and narcotics licenses by Swissmedic for creating cannabis pharmaceuticals. These endorsements give the company the approval to manufacture topnotch medicinal active ingredients from CBD and THC. Canexis is thus positioned to satisfy the escalating demand for medical cannabis in Switzerland and across the globe. The acquisition of these licenses demonstrates the company’s adherence to rigorous regulatory guidelines, thereby boosting its credibility and enhancement towards the fast-paced evolution of the medical cannabis market.

What Are the Top Market Players Propelling the Growth of theCannabis Pharmaceuticals Industry?

Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte’s Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

Which Primary Segments of the Cannabis Pharmaceuticals Market Are Driving Growth and Industry Transformations?

The cannabis pharmaceuticals market covered in this report is segmented –

1) By Product Type: Cannabinoid-Based Pharmaceuticals, Cannabis Extracts, Synthetic Cannabinoids

2) By Formulation Type: Capsules And Tablets, Oils And Tinctures, Topical Solutions

3) By Therapeutic Application: Cancer, Neurological Disorders, Pain Management

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End-User: Hospitals And Clinics, Rehabilitation Centers, Research Organizations

Subsegments:

1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals, CBD-Based Pharmaceuticals, Combination of THC and CBD Pharmaceuticals, Other Cannabinoid-Based Formulations

2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts, Broad-Spectrum Cannabis Extracts, Isolate Cannabis Extracts (CBD Isolate)

3) By Synthetic Cannabinoids: Synthetic THC Analogues, Synthetic CBD Analogues, Synthetic Cannabinoid Receptor Agonists, Designer Synthetic Cannabinoids

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Cannabis Pharmaceuticals Market?# Market?

North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Cannabis Pharmaceuticals Market 2025, By The Business Research Company:

Cannabis Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabis-products-global-market-report

Cannabis Testing Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

Cannabis Cultivation Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabis-cultivation-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: